Literature DB >> 19910136

Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience.

Jean-Pierre Caujolle1, Hamid Mammar, Emmanuel Chamorey, Fabien Pinon, Joël Herault, Pierre Gastaud.   

Abstract

PURPOSE: To present the results of uveal melanomas treated at Nice Teaching Hospital. METHODS AND MATERIALS: This retrospective study included 886 consecutive patients referred to our clinic for the treatment of uveal melanomas by proton beam radiotherapy from June 1991 to December 2007. Survival rates were determined by using Kaplan-Meier estimates, and prognostic factors were evaluated using the log-rank test or Cox model.
RESULTS: The number (percent total) of subjects staged according to the TNM classification system (6th edition) of malignant tumors included 39 stage T1 (4.4%), 420 stage T2 (47.40%), 409 stage T3 (46.16%), and 18 stage T4 (2.03%) patients. The median follow-up was 63.7 months. The Kaplan-Meier overall survival rate at 5 years according to the sixth edition TNM classification was 92% for T1, 89% for T2, 67% for T3, and 62% for T4; and at 10 years, 86% for T1, 78% for T2, 43% for T3, and 41% for T4. Five factors were found to be associated with an increased death rate: advanced age, tumor thickness, largest tumor basal diameter, tumor volume, and tumor volume-to-eyeball volume ratio. The metastasis-free survival rates were 88.3 % at 5 years and 76.4 % at 10 years. The local control rates were 93.9% at 5 years and 92.1% at 10 years. The ocular conservation rates were 91.1% at 5 years and 87.3% at 10 years.
CONCLUSIONS: We report the results of a large series of patients treated for uveal melanomas with a very long follow-up. Despite the large tumor volume treated, our results were similar to previously published findings relating to proton beam therapy. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910136     DOI: 10.1016/j.ijrobp.2009.07.1688

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Surgery vs. radiotherapy in patients with uveal melanoma : Analysis of the SEER database using propensity score matching and weighting.

Authors:  Bum-Sup Jang; Ji Hyun Chang; Sohee Oh; Yu Jin Lim; Il Han Kim
Journal:  Strahlenther Onkol       Date:  2017-09-06       Impact factor: 3.621

2.  Outcomes of Proton Beam Radiotherapy for Large Non-Peripapillary Choroidal and Ciliary Body Melanoma at TRIUMF and the BC Cancer Agency.

Authors:  Britta Weber; Katherine Paton; Roy Ma; Tom Pickles
Journal:  Ocul Oncol Pathol       Date:  2015-07-09

Review 3.  Past, present, and future of radiotherapy for the benefit of patients.

Authors:  Juliette Thariat; Jean-Michel Hannoun-Levi; Arthur Sun Myint; Te Vuong; Jean-Pierre Gérard
Journal:  Nat Rev Clin Oncol       Date:  2012-11-27       Impact factor: 66.675

4.  Brachytherapy of Uveal Melanomas with Ruthenium-106 Plaques

Authors:  Asma Belaïd; Chiraz Nasr; Omar Jmour; Aziz Cherif; Lotfi Kochbati; Hedi Bouguila; Mounir Besbes; Farouk Benna
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

5.  106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma.

Authors:  Ping Jiang; Konstantine Purtskhvanidze; Gerit Kandzia; Dirk Neumann; Ulf Luetzen; Frank-André Siebert; Johann Roider; Juergen Dunst
Journal:  Radiat Oncol       Date:  2020-07-29       Impact factor: 3.481

6.  Three-dimensional MRI-based treatment planning approach for non-invasive ocular proton therapy.

Authors:  E Fleury; P Trnková; E Erdal; M Hassan; B Stoel; M Jaarma-Coes; G Luyten; J Herault; A Webb; J-W Beenakker; J-P Pignol; M Hoogeman
Journal:  Med Phys       Date:  2021-01-17       Impact factor: 4.071

Review 7.  New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.

Authors:  Krzysztof Bilmin; Kamil J Synoradzki; Anna M Czarnecka; Mateusz J Spałek; Tamara Kujawska; Małgorzata Solnik; Piotr Merks; Mario Damiano Toro; Robert Rejdak; Michał Fiedorowicz
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

8.  Outcomes and control rates for I-125 plaque brachytherapy for uveal melanoma: a community-based institutional experience.

Authors:  Aaron Wagner; Andy Chen; Taylor Cook; David Faber; Kirk Winward; William Sause
Journal:  ISRN Ophthalmol       Date:  2014-03-09

9.  Defining Clinical Indications of Proton Beam Therapy at National Level in the Kingdom of Saudi Arabia.

Authors:  Hussain AlHussain; Ali Balbaid; Robert Malyapa; Majid AlOthman; Yasser A Bahadur; Mutahir A Tunio; Mushabbab Al Asiri
Journal:  Saudi Med J       Date:  2019-09       Impact factor: 1.484

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.